Sars-CoV-2 Infection
403
11
26
228
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
60 trials with published results (15%)
Research Maturity
228 completed trials (57% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.4%
30 terminated out of 403 trials
88.4%
+1.8% vs benchmark
15%
60 trials in Phase 3/4
26%
60 of 228 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 228 completed trials
Clinical Trials (403)
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Immunogenicity and Safety of a Single Dose of mRNA SARS-CoV-2 Vaccine in Chinese Adults With Hybrid Immunity
Post Acute Sequelae of COVID-19
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older
A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19
Reducing Respiratory Virus Transmission in Bangladeshi Classrooms
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
LIPId Profile Changes in Inflammatory Conditions Induced by SARS-CORoronavirus-2
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19
Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19
Cellular Senescence and COVID-19 Long-Hauler Syndrome
Remote Assessment of Outpatient With Severe Acute Respiratory Syndrome (SARS-CoV-2)
Cardiovascular Assessment 5 Years After MIS-C
The ACDC Study Assessing Cognitive Deterioration in COVID-19
Safety and Immunogenicity of NVX-CoV2705